NEW YORK (GenomeWeb News) – Oxford Nanopore Technologies today said that it has raised £40 million ($63.7 million) through a private placement of ordinary shares.

Participants in the round include new and existing investors from the US, UK, and mainland Europe, the company said. New investors included Odey Asset Management.

The funds will go toward development of Oxford Nanopore's commercial and manufacturing infrastructure, continued R&D work directed at nanopore sensing, and other corporate purposes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.